Transglutaminase 2 gene ablation protects against renal ischemic injury by blocking constant NF-κB activation

Biochemical and Biophysical Research Communications

Volumn 403, Issue 3-4, 2010, Pages 479-484

  Kim, Dae Seok ^a   Kim, Bora ^a   Tahk, Hongmin ^b   Kim, Dong Hyun ^a   Ahn, Eu Ree ^a   Choi, Changsun ^b   Jeon, Yoon ^a   Park, Seo Young ^a   Lee, Ho ^a   Oh, Seung Hyun ^a   Kim, Soo Youl ^a  

^a National Cancer Center   (South Korea)

^b Chung Ang University   (South Korea)

Author keywords

Ischemia; Nuclear factor B; Renal injury; Transglutaminase 2; Transglutaminase 2 knockout mouse; Unilateral ureteral obstruction

Indexed keywords

CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EMBRYO; EMBRYO CELL; FIBROBLAST; GENE DELETION; HYPOXIA; KIDNEY INJURY; KIDNEY ISCHEMIA; KIDNEY PARENCHYMA; MOUSE; MOUSE MUTANT; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; STRAIN DIFFERENCE; WILD TYPE;

ANIMALS; CYCLOOXYGENASE 2; GTP-BINDING PROTEINS; ISCHEMIA; KIDNEY; KIDNEY DISEASES; MICE; MICE, KNOCKOUT; NF-KAPPA B; TRANSGLUTAMINASES; TUMOR NECROSIS FACTOR-ALPHA;

MUS;

EID: 78650170689     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.11.063     Document Type: Article

References (38)

1. Johnson T.S., El-Koraie A.F., Skill N.J., Baddour N.M., El Nahas A.M., Njloma M., Adam A.G., Griffin M. Tissue transglutaminase and the progression of human renal scarring. J. Am. Soc. Nephrol. 2003, 14:2052-2062.
2. Ikee R., Kobayashi S., Hemmi N., Saigusa T., Namikoshi T., Yamada M., Imakiire T., Kikuchi Y., Suzuki S., Miura S. Involvement of transglutaminase-2 in pathological changes in renal disease. Nephron Clin. Pract. 2007, 105:c139-146.
3. Shweke N., Boulos N., Jouanneau C., Vandermeersch S., Melino G., Dussaule J.C., Chatziantoniou C., Ronco P., Boffa J.J. Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-beta activation and cell infiltration. Am. J. Pathol. 2008, 173:631-642.
4. Le M., Gohr C.M., Rosenthal A.K. Transglutaminase participates in the incorporation of latent TGFbeta into the extracellular matrix of aging articular chondrocytes. Connect. Tissue Res. 2001, 42:245-253.
5. Dickson M.C., Martin J.S., Cousins F.M., Kulkarni A.B., Karlsson S., Akhurst R.J. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development 1995, 121:1845-1854.
6. Meguid El Nahas A., Bello A.K. Chronic kidney disease: the global challenge. Lancet 2005, 365:331-340.
7. Henke N., Schmidt-Ullrich R., Dechend R., Park J.K., Qadri F., Wellner M., Obst M., Gross V., Dietz R., Luft F.C., Scheidereit C., Muller D.N. Vascular endothelial cell-specific NF-kappaB suppression attenuates hypertension-induced renal damage. Circ. Res. 2007, 101:268-276.
8. Tamada S., Asai T., Kuwabara N., Iwai T., Uchida J., Teramoto K., Kaneda N., Yukimura T., Komiya T., Nakatani T., Miura K. Molecular mechanisms and therapeutic strategies of chronic renal injury: the role of nuclear factor kappaB activation in the development of renal fibrosis. J. Pharmacol. Sci. 2006, 100:17-21.
9. Grande M.T., Perez-Barriocanal F., Lopez-Novoa J.M. Role of inflammation in tubulo-interstitial damage associated to obstructive nephropathy. J. Inflamm. (Lond.) 2010, 7.
10. Morrissey J.J., Klahr S. Rapid communication. Enalapril decreases nuclear factor kappa B activation in the kidney with ureteral obstruction. Kidney Int. 1997, 52:926-933.
11. Esteban V., Lorenzo O., Ruperez M., Suzuki Y., Mezzano S., Blanco J., Kretzler M., Sugaya T., Egido J., Ruiz-Ortega M. Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J. Am. Soc. Nephrol. 2004, 15:1514-1529.
12. Mizuguchi Y., Chen J., Seshan S.V., Poppas D.P., Szeto H.H., Felsen D. A novel cell-permeable antioxidant peptide decreases renal tubular apoptosis and damage in unilateral ureteral obstruction. Am. J. Physiol. Renal. Physiol. 2008, 295:F1545-1553.
13. Iismaa S.E., Mearns B.M., Lorand L., Graham R.M. Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders. Physiol. Rev. 2009, 89:991-1023.
14. Kim S.Y. Transglutaminase 2 in inflammation. Front Biosci. 2006, 11:3026-3035.
15. Lee J., Kim Y.S., Choi D.H., Bang M.S., Han T.R., Joh T.H., Kim S.Y. Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia. J. Biol. Chem. 2004, 279:53725-53735.
16. Park S.S., Kim J.M., Kim D.S., Kim I.H., Kim S.Y. Transglutaminase 2 mediates polymer formation of I-kappaBalpha through C-terminal glutamine cluster. J. Biol. Chem. 2006, 281:34965-34972.
17. Kim D.S., Park S.S., Nam B.H., Kim I.H., Kim S.Y. Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation. Cancer Res. 2006, 66:10936-10943.
18. Mirza A., Liu S.L., Frizell E., Zhu J., Maddukuri S., Martinez J., Davies P., Schwarting R., Norton P., Zern M.A. A role for tissue transglutaminase in hepatic injury and fibrogenesis, and its regulation by NF-kappaB. Am. J. Physiol. 1997, 272:G281-288.
19. Liu P., Jenkins N.A., Copeland N.G. A highly efficient recombineering-based method for generating conditional knockout mutations. Genome Res. 2003, 13:476-484.
20. Cotta-de-Almeida V., Schonhoff S., Shibata T., Leiter A., Snapper S.B. A new method for rapidly generating gene-targeting vectors by engineering BACs through homologous recombination in bacteria. Genome Res. 2003, 13:2190-2194.
21. Lee H., Lee D.J., Oh S.P., Park H.D., Nam H.H., Kim J.M., Lim D.S. Mouse emi1 has an essential function in mitotic progression during early embryogenesis. Mol. Cell Biol. 2006, 26:5373-5381.
22. Chevalier R.L., Forbes M.S., Thornhill B.A. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int. 2009, 75:1145-1152.
23. Nanda N., Iismaa S.E., Owens W.A., Husain A., Mackay F., Graham R.M. Targeted inactivation of Gh/tissue transglutaminase II. J. Biol. Chem. 2001, 276:20673-20678.
24. Mastroberardino P.G., Iannicola C., Nardacci R., Bernassola F., De Laurenzi V., Melino G., Moreno S., Pavone F., Oliverio S., Fesus L., Piacentini M. 'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease. Cell Death Differ. 2002, 9:873-880.
25. Molitoris B.A. New insights into the cell biology of ischemic acute renal failure. J. Am. Soc. Nephrol. 1991, 1:1263-1270.
26. Kennedy S.E., Erlich J.H. Murine renal ischaemia-reperfusion injury. Nephrology (Carlton) 2008, 13:390-396.
27. Song S., Meyer M., Turk T.R., Wilde B., Feldkamp T., Assert R., Wu K., Kribben A., Witzke O. Serum cystatin C in mouse models: a reliable and precise marker for renal function and superior to serum creatinine. Nephrol. Dial. Transpl. 2009, 24:1157-1161.
28. Johnson T.S., Fisher M., Haylor J.L., Hau Z., Skill N.J., Jones R., Saint R., Coutts I., Vickers M.E., El Nahas A.M., Griffin M. Transglutaminase inhibition reduces fibrosis and preserves function in experimental chronic kidney disease. J. Am. Soc. Nephrol. 2007, 18:3078-3088.
29. Falasca L., Farrace M.G., Rinaldi A., Tuosto L., Melino G., Piacentini M. Transglutaminase type II is involved in the pathogenesis of endotoxic shock. J. Immunol. 2008, 180:2616-2624.
30. Parving H.H. Diabetic nephropathy: prevention and treatment. Kidney Int. 2001, 60:2041-2055.
31. Molitch M.E., DeFronzo R.A., Franz M.J., Keane W.F., Mogensen C.E., Parving H.H. Diabetic nephropathy. Diabetes Care 2003, 26(Suppl. 1):S94-98.
32. Skill N.J., Johnson T.S., Coutts I.G., Saint R.E., Fisher M., Huang L., El Nahas A.M., Collighan R.J., Griffin M. Inhibition of transglutaminase activity reduces extracellular matrix accumulation induced by high glucose levels in proximal tubular epithelial cells. J. Biol. Chem. 2004, 279:47754-47762.
33. El Nahas A.M., Abo-Zenah H., Skill N.J., Bex S., Wild G., Griffin M., Johnson T.S. Elevated epsilon-(gamma-glutamyl)lysine in human diabetic nephropathy results from increased expression and cellular release of tissue transglutaminase. Nephron Clin. Pract. 2004, 97:c108-117.
34. Huang L., Haylor J.L., Hau Z., Jones R.A., Vickers M.E., Wagner B., Griffin M., Saint R.E., Coutts I.G., El Nahas A.M., Johnson T.S. Transglutaminase inhibition ameliorates experimental diabetic nephropathy. Kidney Int. 2009, 76:383-394.
35. Maiuri L., Luciani A., Giardino I., Raia V., Villella V.R., D'Apolito M., Pettoello-Mantovani M., Guido S., Ciacci C., Cimmino M., Cexus O.N., Londei M., Quaratino S. Tissue transglutaminase activation modulates inflammation in cystic fibrosis via PPARgamma down-regulation. J. Immunol. 2008, 180:7697-7705.
36. Johnson T.S., Griffin M., Thomas G.L., Skill J., Cox A., Yang B., Nicholas B., Birckbichler P.J., Muchaneta-Kubara C., Meguid El Nahas A. The role of transglutaminase in the rat subtotal nephrectomy model of renal fibrosis. J. Clin. Invest. 1997, 99:2950-2960.
37. Murtaugh M.P., Arend W.P., Davies P.J. Induction of tissue transglutaminase in human peripheral blood monocytes. J. Exp. Med. 1984, 159:114-125.
38. Seiving B., Ohlsson K., Linder C., Stenberg P. Transglutaminase differentiation during maturation of human blood monocytes to macrophages. Eur. J. Haematol. 1991, 46:263-271.